Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients. - sprookjes - yvandenbroek - TriplyDB

Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients.

Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients.

http://www.wikidata.org/entity/Q34829079

about

Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection Response: Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients (Diabetes Metab J 2011;35:41-9).C-Peptide Is Independently Associated with an Increased Risk of Coronary Artery Disease in T2DM Subjects: A Cross-Sectional Study Cardiovascular diseases risk evaluation in newly diagnosed type-2 diabetics: An association of novel biomarkers apo proteins and C-peptide.Serum C-peptide levels and risk of death among adults without diabetes mellitus.Interdependencies among Selected Pro-Inflammatory Markers of Endothelial Dysfunction, C-Peptide, Anti-Inflammatory Interleukin-10 and Glucose Metabolism Disturbance in Obese Women Gender differences in the association of insulin resistance and high-sensitivity c-reactive protein in obese adolescents.C-peptide: a new mediator of atherosclerosis in diabetes Lipid and inflammatory biomarker profiles in early insulin resistance.Letter: Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetes Patients (Diabetes Metab J 2011;35:41-9).Hemolysis Affects C-Peptide Immunoassay.The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study.C-peptide as a risk factor of coronary artery disease in the general population.

P2860

Q28480545-08D51056-3192-421E-A0BC-984495A38B46 Q35067262-9FD26F8B-F1DF-410B-A409-1E744AC2FB92 Q35670690-D0847888-8996-40A3-8567-9353188D1CD8 Q36436458-50283539-65AB-4111-9ACD-C03EB8AC06AC Q36923404-E8C90242-8C3A-40C5-B4A6-841F51116C50 Q37096903-9DDE5A33-A9CF-49F5-82C4-C5D1121B5A7E Q37681809-9662EF3E-4A5F-4FEC-A7F6-9C96453A1393 Q38006686-E42621C8-6AC9-4F01-928C-04A9116D5EAB Q40644407-D53D5437-7423-456B-85DF-8092B76C10FB Q42773430-5B68BC46-6F7A-4073-BB98-6AB1B65F006B Q48666369-0818E430-E0D7-47A5-BBD3-3E7E387E81FC Q49221219-1E6226FC-FE40-4237-9574-2BC539CDED6C Q51307657-8BC29756-6375-4054-813A-C4367687DD02

P2860

Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients.

http://www.wikidata.org/entity/Q34829079

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@ast

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@en

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@nl

type

label

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@ast

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@en

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@nl

prefLabel

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@ast

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@en

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@nl

P1433

Q34829079-B9B13DDB-9330-479D-BC51-48DB6066196E

P1476

Q34829079-E54F4B07-5C86-4C27-AAA7-883FFB118908

P2093

Q34829079-397FDF9D-5103-438C-AE63-2226897AD986

Q34829079-3A93C552-C2B0-44E1-8B79-D81C27D4BDF2

Q34829079-48D0DBAC-926C-401A-9D10-06255713B49A

Q34829079-5214DFD4-D17C-4431-9235-8CA4A81E1A4F

Q34829079-5B1829C9-AB54-4964-9563-94191C572ECB

Q34829079-9431171C-7187-4438-8B2C-E1DB0C43F72C

Q34829079-A530FC28-E024-43EE-A256-14EFFDA59A37

Q34829079-C4CAD56D-5878-4389-BB01-6FC2C3837097

Q34829079-C59FAC4E-EA52-4E11-86CC-9A58BFEBBF60

Q34829079-F64E5D6E-A9C1-476F-BD32-6C958BBF07C7

P2860

Q34829079-02F45628-E9C0-4410-AA0D-EEA044DE558A

Q34829079-0992CEEE-F3E1-4284-BC9D-9513F77FAE51

Q34829079-1E292434-1DA5-4698-B8F7-6E8E1DA11BBD

Q34829079-277955A1-2088-4492-8E67-112B46B0F4CE

Q34829079-2C4D4684-11EC-4393-AE28-A87272E6C2FB

Q34829079-322FFE98-DAE3-463E-A4BB-EC5C940E3AD1

Q34829079-37265218-A5D9-41EE-8F6E-28CDD5E359B6

Q34829079-3ABC51BC-0014-4F96-BE08-9A699644B3DB

Q34829079-3D5F472C-F4D8-45B7-9680-A17ABDDCF47B

Q34829079-4C2CBC83-DB3A-4851-B8F5-038E11FC0E1C

P304

Q34829079-6A1D9702-244E-4CE8-9072-216C3B6E1D7A

P31

Q34829079-B4D6C5A8-D65D-456A-8B29-688AEF49EBBE

P356

Q34829079-ABB379FD-8AB2-4212-9E85-8E057FA2675D

P433

Q34829079-5DCE00BC-C4C1-4F9E-9BF4-F10829A5735D

P478

Q34829079-2F4F5C32-3932-4837-88FD-FFECFC08CA7A

P577

Q34829079-4D6A9378-F430-4F76-8D69-057F1B99EAFC

P5875

Q34829079-7CF6D537-7E1B-4105-9D98-A02ED5A7A576

P698

Q34829079-FA228984-C5B1-4024-B249-2091BF4D41DB

P921

Q34829079-B55D65D6-EE69-471E-8D51-8E501EE0CB00

P932

Q34829079-E3A6185E-A00C-4837-974E-228B2DDCB20F

P356

DMJ.2011.35.1.41

P1433

Diabetes & metabolism journal

P1476

Basal C-peptide Level as a Sur ...... s in Type 2 Diabetic Patients.

@en

P2093

Byung-Joon Kim

http://www.w3.org/2001/XMLSchema#string

Dae-Ho Lee

http://www.w3.org/2001/XMLSchema#string

Dong-Mee Lim

http://www.w3.org/2001/XMLSchema#string

Gwan-Pyo Koh

http://www.w3.org/2001/XMLSchema#string

In-Geol Song

http://www.w3.org/2001/XMLSchema#string

Jang-Han Jung

http://www.w3.org/2001/XMLSchema#string

Kang-Woo Lee

http://www.w3.org/2001/XMLSchema#string

Keun-Young Park

http://www.w3.org/2001/XMLSchema#string

Sung-Tae Kim

http://www.w3.org/2001/XMLSchema#string

Youn-Zoo Cho

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

The metabolic syndrome--a new worldwide definition

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

New roles for Src kinases in control of cell survival and angiogenesis.

Report of the expert committee on the diagnosis and classification of diabetes mellitus.

Insulin resistance and atherosclerosis.

Molecular effects of proinsulin C-peptide.

P304

41-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4093/DMJ.2011.35.1.41

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51093394

http://www.w3.org/2001/XMLSchema#string

P698

21537412

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

3080577

http://www.w3.org/2001/XMLSchema#string